# Phase 2a Study to Evaluate Safety and Explore Efficacy of J2H-1702 for NASH

> **NCT06297434** · PHASE2 · COMPLETED · sponsor: **J2H Biotech** · enrollment: 87 (actual)

## Conditions studied

- Non-alcoholic Steatohepatitis

## Interventions

- **DRUG:** J2H-1702
- **DRUG:** J2H-1702
- **DRUG:** J2H-1702
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06297434
- **Lead sponsor:** J2H Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-15
- **Primary completion:** 2025-06-26
- **Final completion:** 2025-11-05
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2025-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06297434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06297434, "Phase 2a Study to Evaluate Safety and Explore Efficacy of J2H-1702 for NASH". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06297434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*